What is Pacira Biosciences Inc's earnings per share (EPS)?

Pacira Biosciences Inc (PCRX) reported diluted earnings per share of $0.16 for fiscal year 2025. This represents a 107.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pacira Biosciences Inc Financials

PCRX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Pacira Biosciences Inc (PCRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 56/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Pacira Biosciences Inc has an operating margin of 2.6%, meaning the company retains $3 of operating profit per $100 of revenue. This below-average margin results in a low score of 28/100, suggesting thin profitability after operating expenses. This is up from -10.5% the prior year.

Growth

Pacira Biosciences Inc's revenue grew a modest 3.6% year-over-year to $726.4M. This slow but positive growth earns a score of 39/100.

Leverage

Pacira Biosciences Inc carries a low D/E ratio of 0.54, meaning only $0.54 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.54, Pacira Biosciences Inc holds $4.54 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 90/100.

Cash Flow

Pacira Biosciences Inc converts 18.8% of revenue into free cash flow ($136.7M). This strong cash generation earns a score of 72/100.

Returns

Pacira Biosciences Inc generates a 1.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 13/100. This is up from -12.8% the prior year.

Altman Z-Score Distress

1.77

Pacira Biosciences Inc scores 1.77, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($919.1M) relative to total liabilities ($571.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Strong

8/9

Pacira Biosciences Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

21.61x

For every $1 of reported earnings, Pacira Biosciences Inc generates $21.61 in operating cash flow ($152.0M OCF vs $7.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

1.1x

Pacira Biosciences Inc earns $1.1 in operating income for every $1 of interest expense ($19.2M vs $17.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$726.4M

YoY+3.6%

5Y CAGR+11.1%

10Y CAGR+11.3%

Pacira Biosciences Inc generated $726.4M in revenue in fiscal year 2025. This represents an increase of 3.6% from the prior year.

EBITDA

$110.2M

YoY+1935.7%

5Y CAGR+10.7%

10Y CAGR+18.1%

Pacira Biosciences Inc's EBITDA was $110.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1935.7% from the prior year.

Net Income

$7.0M

YoY+107.1%

5Y CAGR-45.4%

10Y CAGR+14.3%

Pacira Biosciences Inc reported $7.0M in net income in fiscal year 2025. This represents an increase of 107.1% from the prior year.

EPS (Diluted)

$0.16

YoY+107.4%

5Y CAGR-45.5%

10Y CAGR+14.9%

Pacira Biosciences Inc earned $0.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 107.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$136.7M

YoY-23.5%

5Y CAGR+28.4%

Pacira Biosciences Inc generated $136.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 23.5% from the prior year.

Cash & Debt

$158.5M

YoY-42.7%

5Y CAGR+9.7%

10Y CAGR+11.3%

Pacira Biosciences Inc held $158.5M in cash against $372.2M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

41M

YoY-11.1%

5Y CAGR-1.2%

10Y CAGR+1.1%

Pacira Biosciences Inc had 41M shares outstanding in fiscal year 2025. This represents a decrease of 11.1% from the prior year.

Margins & Returns

Gross Margin

79.4%

YoY+3.7pp

5Y CAGR+6.7pp

10Y CAGR+8.2pp

Pacira Biosciences Inc's gross margin was 79.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.7 percentage points from the prior year.

Operating Margin

2.6%

YoY+13.1pp

5Y CAGR-8.1pp

10Y CAGR-1.2pp

Pacira Biosciences Inc's operating margin was 2.6% in fiscal year 2025, reflecting core business profitability. This is up 13.1 percentage points from the prior year.

Net Margin

1.0%

YoY+15.2pp

5Y CAGR-32.9pp

10Y CAGR+0.2pp

Pacira Biosciences Inc's net profit margin was 1.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 15.2 percentage points from the prior year.

Return on Equity

1.0%

YoY+13.8pp

5Y CAGR-22.5pp

10Y CAGR+0.2pp

Pacira Biosciences Inc's ROE was 1.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 13.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$117.3M

YoY+43.8%

5Y CAGR+14.6%

10Y CAGR+15.1%

Pacira Biosciences Inc invested $117.3M in research and development in fiscal year 2025. This represents an increase of 43.8% from the prior year.

Share Buybacks

$148.3M

YoY+493.3%

Pacira Biosciences Inc spent $148.3M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 493.3% from the prior year.

Capital Expenditures

$15.3M

YoY+44.2%

5Y CAGR-16.5%

10Y CAGR-9.2%

Pacira Biosciences Inc invested $15.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 44.2% from the prior year.

PCRX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$726.4M+3.6%	$701.0M+3.9%	$675.0M+1.2%	$666.8M+23.1%	$541.5M+26.0%	$429.6M
Cost of Revenue	$149.7M-12.1%	$170.4M-7.7%	$184.7M-7.3%	$199.3M+42.1%	$140.3M+19.5%	$117.3M
Gross Profit	$576.7M+8.7%	$530.5M+8.2%	$490.3M+4.9%	$467.5M+16.5%	$401.3M+28.5%	$312.3M
R&D Expenses	$117.3M+43.8%	$81.6M+7.0%	$76.3M-10.1%	$84.8M+52.7%	$55.5M-6.5%	$59.4M
SG&A Expenses	$368.8M+25.4%	$294.1M+9.2%	$269.4M+5.9%	$254.5M+27.7%	$199.3M+3.0%	$193.5M
Operating Income	$19.2M+126.2%	-$73.4M-183.7%	$87.7M+46.1%	$60.0M-33.3%	$89.9M+94.0%	$46.4M
Interest Expense	$17.4M+5.3%	$16.6M-18.4%	$20.3M-49.2%	$40.0M+25.9%	$31.8M+23.7%	$25.7M
Income Tax	$9.8M-73.0%	$36.5M+84.6%	$19.7M+857.4%	-$2.6M-118.1%	$14.4M+111.5%	-$125.4M
Net Income	$7.0M+107.1%	-$99.6M-337.3%	$42.0M+163.7%	$15.9M-62.1%	$42.0M-71.2%	$145.5M
EPS (Diluted)	$0.16+107.4%	$-2.15-341.6%	$0.89+161.8%	$0.34-63.0%	$0.92-72.4%	$3.33

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$196.9M+9.7%	$179.5M-0.9%	$181.1M+7.2%	$168.9M-9.8%	$187.3M+11.1%	$168.6M-5.3%	$178.0M+6.5%	$167.1M
Cost of Revenue	$40.3M+17.6%	$34.3M-16.1%	$40.9M+19.1%	$34.3M-14.0%	$39.9M+2.6%	$38.9M-12.2%	$44.3M-6.7%	$47.4M
Gross Profit	$156.6M+7.8%	$145.2M+3.6%	$140.2M+4.2%	$134.6M-8.7%	$147.4M+13.6%	$129.7M-3.0%	$133.8M+11.7%	$119.7M
R&D Expenses	$37.8M+45.6%	$26.0M-7.9%	$28.2M+11.3%	$25.3M+6.0%	$23.9M+25.1%	$19.1M-6.1%	$20.3M+11.5%	$18.2M
SG&A Expenses	$101.6M+10.7%	$91.8M+3.6%	$88.6M+2.1%	$86.8M+9.0%	$79.6M+7.1%	$74.3M+9.1%	$68.1M-5.4%	$72.0M
Operating Income	$2.3M-63.2%	$6.4M-25.1%	$8.5M+327.1%	$2.0M-91.9%	$24.7M+117.7%	-$139.5M-594.1%	$28.2M+113.7%	$13.2M
Interest Expense	$3.9M-9.0%	$4.3M-8.9%	$4.7M+2.5%	$4.6M-2.1%	$4.7M-0.2%	$4.7M+20.7%	$3.9M+17.1%	$3.3M
Income Tax	-$1.1M-126.1%	$4.1M+40.1%	$2.9M-25.0%	$3.9M-58.9%	$9.5M+105.7%	$4.6M-74.0%	$17.7M+279.7%	$4.7M
Net Income	$1.6M-69.9%	$5.4M+212.1%	-$4.8M-200.7%	$4.8M-70.0%	$16.0M+111.2%	-$143.5M-859.6%	$18.9M+110.3%	$9.0M
EPS (Diluted)	N/A	$0.12+209.1%	$-0.11-210.0%	$0.10	N/A	$-3.11-897.4%	$0.39+105.3%	$0.19

PCRX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.3B-18.6%	$1.6B-1.3%	$1.6B-6.4%	$1.7B-19.0%	$2.1B+62.8%	$1.3B
Current Assets	$548.0M-26.5%	$745.1M+46.1%	$510.0M+2.3%	$498.3M-42.5%	$866.0M+32.9%	$651.6M
Cash & Equivalents	$158.5M-42.7%	$276.8M+80.5%	$153.3M+47.2%	$104.1M-82.2%	$585.6M+485.8%	$100.0M
Inventory	$152.9M+22.0%	$125.3M+20.1%	$104.4M+8.6%	$96.1M-2.5%	$98.5M+52.4%	$64.7M
Accounts Receivable	$124.1M+9.5%	$113.3M+7.3%	$105.6M+7.3%	$98.4M+2.2%	$96.3M+81.6%	$53.0M
Goodwill	$20.2M	$0-100.0%	$163.2M0.0%	$163.2M+12.4%	$145.2M+45.9%	$99.5M
Total Liabilities	$571.8M-26.2%	$775.2M+10.1%	$704.3M-22.3%	$906.2M-32.6%	$1.3B+105.4%	$654.8M
Current Liabilities	$120.6M-61.1%	$309.9M+218.2%	$97.4M-34.1%	$147.8M-71.6%	$521.1M+105.7%	$253.3M
Long-Term Debt	$372.2M-3.0%	$383.5M-26.6%	$522.4M-24.2%	$689.5M	N/A	N/A
Total Equity	$693.1M-11.0%	$778.3M-10.5%	$870.1M+12.3%	$775.0M+6.1%	$730.4M+17.9%	$619.7M
Retained Earnings	-$199.3M+3.4%	-$206.4M-93.2%	-$106.8M+28.2%	-$148.8M+29.8%	-$211.9M+16.5%	-$253.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.3B-2.5%	$1.3B-15.6%	$1.5B-3.1%	$1.6B+2.1%	$1.6B+2.1%	$1.5B-7.6%	$1.6B+4.0%	$1.6B
Current Assets	$548.0M-2.6%	$562.8M-24.5%	$745.6M-1.9%	$760.0M+2.0%	$745.1M+8.0%	$690.0M+9.1%	$632.2M+16.4%	$543.1M
Cash & Equivalents	$158.5M+7.4%	$147.6M-50.9%	$300.5M+5.9%	$283.6M+2.5%	$276.8M+12.5%	$246.0M-0.4%	$247.1M+34.2%	$184.1M
Inventory	$152.9M-3.1%	$157.7M+6.4%	$148.2M+10.8%	$133.8M+6.8%	$125.3M+12.0%	$111.9M+8.1%	$103.4M+6.9%	$96.8M
Accounts Receivable	$124.1M+7.6%	$115.3M+0.8%	$114.4M+9.2%	$104.7M-7.6%	$113.3M+12.6%	$100.7M-3.9%	$104.8M+3.1%	$101.6M
Goodwill	$20.2M-0.5%	$20.3M+0.1%	$20.3M-5.7%	$21.5M	$0	$0-100.0%	$163.2M0.0%	$163.2M
Total Liabilities	$571.8M+0.3%	$570.4M-26.8%	$779.5M-1.1%	$788.1M+1.7%	$775.2M+0.4%	$772.1M+0.6%	$767.5M+11.1%	$691.2M
Current Liabilities	$120.6M+12.6%	$107.1M-65.8%	$313.2M-0.5%	$314.7M+1.6%	$309.9M+1.1%	$306.4M+230.6%	$92.7M-0.8%	$93.4M
Long-Term Debt	$372.2M-1.2%	$376.7M-35.1%	$580.5M-0.5%	$583.4M+52.1%	$383.5M	N/A	N/A	N/A
Total Equity	$693.1M-4.7%	$727.2M-4.0%	$757.8M-5.1%	$798.5M+2.6%	$778.3M+3.8%	$749.6M-14.8%	$879.3M-1.4%	$892.2M
Retained Earnings	-$199.3M+0.8%	-$201.0M+2.6%	-$206.4M-2.4%	-$201.5M+2.3%	-$206.4M+7.2%	-$222.4M-181.8%	-$78.9M+19.3%	-$97.8M

PCRX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$152.0M-19.7%	$189.4M+22.5%	$154.6M+6.5%	$145.3M+15.6%	$125.7M+63.2%	$77.0M
Capital Expenditures	$15.3M+44.2%	$10.6M-29.8%	$15.2M-49.6%	$30.1M-34.4%	$45.9M+21.3%	$37.8M
Free Cash Flow	$136.7M-23.5%	$178.8M+28.1%	$139.5M+21.1%	$115.2M+44.3%	$79.9M+103.5%	$39.2M
Investing Cash Flow	$99.5M+219.5%	-$83.3M-207.4%	$77.5M+134.4%	-$225.2M-983.1%	-$20.8M+92.5%	-$277.6M
Financing Cash Flow	-$369.6M-2228.8%	$17.4M+109.5%	-$183.0M+54.4%	-$401.5M-205.5%	$380.7M+71.2%	$222.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$148.3M+493.3%	$25.0M	$0	$0	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$43.7M-28.2%	$60.8M+406.4%	$12.0M-66.1%	$35.5M+7.0%	$33.1M-38.6%	$53.9M+1.3%	$53.2M+8.4%	$49.1M
Capital Expenditures	$218K-94.4%	$3.9M+43.5%	$2.7M-68.4%	$8.5M+303.6%	$2.1M-48.2%	$4.1M+157.4%	$1.6M-43.9%	$2.8M
Free Cash Flow	$43.5M-23.7%	$57.0M+511.5%	$9.3M-65.4%	$26.9M-13.2%	$31.0M-37.8%	$49.8M-3.5%	$51.6M+11.6%	$46.3M
Investing Cash Flow	$19.3M-55.7%	$43.6M-29.8%	$62.2M+342.5%	-$25.6M-6864.4%	-$368K+99.3%	-$52.2M-242.8%	-$15.2M+2.0%	-$15.5M
Financing Cash Flow	-$51.7M+79.9%	-$257.5M-347.7%	-$57.5M-1820.7%	-$3.0M-53.1%	-$2.0M+31.3%	-$2.8M-111.4%	$25.0M+986.8%	-$2.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$48.2M-3.6%	$50.0M	N/A	N/A	$0	$0	N/A	N/A

PCRX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	79.4%+3.7pp	75.7%+3.0pp	72.6%+2.5pp	70.1%-4.0pp	74.1%+1.4pp	72.7%
Operating Margin	2.6%+13.1pp	-10.5%-23.5pp	13.0%+4.0pp	9.0%-7.6pp	16.6%+5.8pp	10.8%
Net Margin	1.0%+15.2pp	-14.2%-20.4pp	6.2%+3.8pp	2.4%-5.4pp	7.8%-26.1pp	33.9%
Return on Equity	1.0%+13.8pp	-12.8%-17.6pp	4.8%+2.8pp	2.1%-3.7pp	5.8%-17.7pp	23.5%
Return on Assets	0.6%+7.0pp	-6.4%-9.1pp	2.7%+1.7pp	0.9%-1.1pp	2.0%-9.4pp	11.4%
Current Ratio	4.54+2.1	2.40-2.8	5.24+1.9	3.37+1.7	1.66-0.9	2.57
Debt-to-Equity	0.54+0.0	0.49-0.1	0.60-0.3	0.89-1.0	1.84+0.8	1.06
FCF Margin	18.8%-6.7pp	25.5%+4.8pp	20.7%+3.4pp	17.3%+2.5pp	14.8%+5.6pp	9.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	79.5%-1.4pp	80.9%+3.5pp	77.4%-2.3pp	79.7%+1.0pp	78.7%+1.8pp	77.0%+1.8pp	75.1%+3.5pp	71.6%
Operating Margin	1.2%-2.4pp	3.5%-1.1pp	4.7%+3.5pp	1.2%-12.0pp	13.2%+96.0pp	-82.8%-98.6pp	15.9%+7.9pp	7.9%
Net Margin	0.8%-2.2pp	3.0%+5.7pp	-2.7%-5.5pp	2.9%-5.7pp	8.6%+93.7pp	-85.1%-95.7pp	10.6%+5.2pp	5.4%
Return on Equity	0.2%-0.5pp	0.8%+1.4pp	-0.6%-1.2pp	0.6%-1.5pp	2.1%+21.2pp	-19.1%-21.3pp	2.1%+1.1pp	1.0%
Return on Assets	0.1%-0.3pp	0.4%+0.7pp	-0.3%-0.6pp	0.3%-0.7pp	1.0%+10.5pp	-9.4%-10.6pp	1.1%+0.6pp	0.6%
Current Ratio	4.54-0.7	5.26+2.9	2.38-0.0	2.41+0.0	2.40+0.2	2.25-4.6	6.82+1.0	5.81
Debt-to-Equity	0.54+0.0	0.52-0.2	0.77+0.0	0.73+0.2	0.49-0.5	1.03+0.2	0.87+0.1	0.77
FCF Margin	22.1%-9.7pp	31.7%+26.6pp	5.1%-10.8pp	15.9%-0.6pp	16.6%-13.0pp	29.6%+0.5pp	29.0%+1.3pp	27.7%

Similar Companies

Collegium Pharmaceutical Inc COLL

$1.0B

Dynavax Technolo DVAX

$1.8B

Avadel Pharmaceu AVDL

$2.1B

Harrow Health Inc HROW

$1.3B

Amphastar Pharma AMPH

$927.8M

Frequently Asked Questions

What is Pacira Biosciences Inc's annual revenue?

Pacira Biosciences Inc (PCRX) reported $726.4M in total revenue for fiscal year 2025. This represents a 3.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Pacira Biosciences Inc's revenue growing?

Pacira Biosciences Inc (PCRX) revenue grew by 3.6% year-over-year, from $701.0M to $726.4M in fiscal year 2025.

Is Pacira Biosciences Inc profitable?

Yes, Pacira Biosciences Inc (PCRX) reported a net income of $7.0M in fiscal year 2025, with a net profit margin of 1.0%.

What is Pacira Biosciences Inc's EBITDA?

Pacira Biosciences Inc (PCRX) had EBITDA of $110.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Pacira Biosciences Inc have?

As of fiscal year 2025, Pacira Biosciences Inc (PCRX) had $158.5M in cash and equivalents against $372.2M in long-term debt.

What is Pacira Biosciences Inc's gross margin?

Pacira Biosciences Inc (PCRX) had a gross margin of 79.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Pacira Biosciences Inc's operating margin?

Pacira Biosciences Inc (PCRX) had an operating margin of 2.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Pacira Biosciences Inc's net profit margin?

Pacira Biosciences Inc (PCRX) had a net profit margin of 1.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Pacira Biosciences Inc's return on equity (ROE)?

Pacira Biosciences Inc (PCRX) has a return on equity of 1.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pacira Biosciences Inc's free cash flow?

Pacira Biosciences Inc (PCRX) generated $136.7M in free cash flow during fiscal year 2025. This represents a -23.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pacira Biosciences Inc's operating cash flow?

Pacira Biosciences Inc (PCRX) generated $152.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pacira Biosciences Inc's total assets?

Pacira Biosciences Inc (PCRX) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Pacira Biosciences Inc's capital expenditures?

Pacira Biosciences Inc (PCRX) invested $15.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Pacira Biosciences Inc spend on research and development?

Pacira Biosciences Inc (PCRX) invested $117.3M in research and development during fiscal year 2025.

Does Pacira Biosciences Inc buy back shares?

Yes, Pacira Biosciences Inc (PCRX) spent $148.3M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Pacira Biosciences Inc have outstanding?

Pacira Biosciences Inc (PCRX) had 41M shares outstanding as of fiscal year 2025.

What is Pacira Biosciences Inc's current ratio?

Pacira Biosciences Inc (PCRX) had a current ratio of 4.54 as of fiscal year 2025, which is generally considered healthy.

What is Pacira Biosciences Inc's debt-to-equity ratio?

Pacira Biosciences Inc (PCRX) had a debt-to-equity ratio of 0.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pacira Biosciences Inc's return on assets (ROA)?

Pacira Biosciences Inc (PCRX) had a return on assets of 0.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pacira Biosciences Inc's Altman Z-Score?

Pacira Biosciences Inc (PCRX) has an Altman Z-Score of 1.77, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Pacira Biosciences Inc's Piotroski F-Score?

Pacira Biosciences Inc (PCRX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pacira Biosciences Inc's earnings high quality?

Pacira Biosciences Inc (PCRX) has an earnings quality ratio of 21.61x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pacira Biosciences Inc cover its interest payments?

Pacira Biosciences Inc (PCRX) has an interest coverage ratio of 1.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Pacira Biosciences Inc?

Pacira Biosciences Inc (PCRX) scores 56 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.